Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
Approximately 68 weeks including a 4‐week screening period, a 52‐week treatment period, and 12 weeks of follow‐up.
Epistemonikos ID: 1d06e60d2432e5f01e092cbe2f0de1ade2a8c2e9
First added on: May 22, 2024